Structures by: Shao C.
Total: 34
C25H42O2
C25H42O2
Organic Letters (2013) 15, 10 2522
a=12.6439(3)Å b=6.8702(2)Å c=13.2201(4)Å
α=90.00° β=97.454(2)° γ=90.00°
(C25H42O)(H2O)0.75
(C25H42O)(H2O)0.75
Organic Letters (2013) 15, 10 2522
a=29.5357(3)Å b=15.7962(2)Å c=20.0056(2)Å
α=90.00° β=96.3130(10)° γ=90.00°
C17H15BrO2
C17H15BrO2
Organic letters (2010) 12, 17 3820-3823
a=6.8149(10)Å b=14.637(2)Å c=14.679(2)Å
α=90.00° β=90.00° γ=90.00°
C12H14O4
C12H14O4
Organic letters (2008) 10, 18 4101-4104
a=6.1336(7)Å b=11.7280(14)Å c=14.5571(17)Å
α=90.00° β=90.00° γ=90.00°
C28H37Cl2O8Rh2
C28H37Cl2O8Rh2
Organic letters (2008) 10, 18 4101-4104
a=9.7534(10)Å b=9.9312(10)Å c=28.882(3)Å
α=90.00° β=90.00° γ=90.00°
C16H24O5
C16H24O5
Journal of natural products (2011) 74, 5 1230-1235
a=10.9434(2)Å b=12.4201(2)Å c=22.1019(4)Å
α=90.00° β=90.00° γ=90.00°
C16H24O5
C16H24O5
Journal of natural products (2011) 74, 5 1230-1235
a=8.73800(10)Å b=12.27280(10)Å c=14.31590(10)Å
α=90.00° β=97.1630(10)° γ=90.00°
C14H22O4
C14H22O4
Journal of natural products (2011) 74, 5 1230-1235
a=7.3125(2)Å b=12.4303(5)Å c=13.9596(7)Å
α=90.00° β=90.00° γ=90.00°
C22H17OPS
C22H17OPS
Organic & biomolecular chemistry (2017) 15, 3 545-549
a=10.8152(5)Å b=8.5569(3)Å c=20.0431(9)Å
α=90.00° β=95.275(4)° γ=90.00°
C16H10O11Pr,C9H8N2
C16H10O11Pr,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.097(5)Å b=8.503(3)Å c=19.088(6)Å
α=90° β=114.725(4)° γ=90°
C16H10EuO11,C9H8N2
C16H10EuO11,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.213(3)Å b=8.5404(14)Å c=19.151(4)Å
α=90° β=114.685(3)° γ=90°
C16H10NdO11,C9H8N2
C16H10NdO11,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.2535(18)Å b=8.5688(9)Å c=19.213(2)Å
α=90° β=114.7074(16)° γ=90°
C16H10CeO11,C9H8N2
C16H10CeO11,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.2883(10)Å b=8.5827(5)Å c=19.2359(12)Å
α=90° β=114.7250(9)° γ=90°
C16H10O11Sm,C9H8N2
C16H10O11Sm,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.2397(14)Å b=8.5555(7)Å c=19.2033(17)Å
α=90° β=114.7534(12)° γ=90°
C16H10LaO11,C9H8N2
C16H10LaO11,C9H8N2
Dalton transactions (Cambridge, England : 2003) (2020) 49, 37 13003-13016
a=16.398(8)Å b=8.627(4)Å c=19.391(9)Å
α=90° β=115.01° γ=90°
C27H34OSi2
C27H34OSi2
Chemical communications (Cambridge, England) (2018) 54, 75 10598-10601
a=9.2327(8)Å b=9.5206(9)Å c=17.1628(19)Å
α=94.671(4)° β=104.862(4)° γ=112.646(3)°
Aquabis(nicotinamide-κN)(thiocyanato-κN)copper(II)
C14H14CuN6O3S2
Acta Crystallographica Section E (2008) 64, 2 m314-m314
a=11.078(5)Å b=8.950(4)Å c=18.702(9)Å
α=90.00° β=90.333(8)° γ=90.00°
Trans-Tetraaquabis(nicotinamide-κN)cadmium(II) biphenyl-4,4-disulfonate
C12H20CdN4O6,C12H8O6S2
Acta Crystallographica Section E (2008) 64, 2 m424-m424
a=14.742(8)Å b=6.899(4)Å c=15.292(8)Å
α=90.00° β=110.980(9)° γ=90.00°
2-(2,3-Difluorophenyl)ethyl toluene-4-sulfonate
C15H14F2O3S
Acta Crystallographica Section E (2010) 66, 2 o283
a=7.487(12)Å b=8.386(14)Å c=12.69(2)Å
α=91.67(3)° β=96.51(3)° γ=105.65(3)°
C85H55Cd2N12O10
C85H55Cd2N12O10
ACS applied materials & interfaces (2017) 9, 20 17208-17217
a=10.5207(6)Å b=19.5694(11)Å c=19.8195(12)Å
α=85.5670(10)° β=76.2310(10)° γ=85.8780(10)°
Ent-12
C14H14N2O
ACS Medicinal Chemistry Letters (2020)
a=5.7576(3)Å b=6.6825(4)Å c=29.3671(16)Å
α=90° β=90° γ=90°
9
C16H18N2O
ACS Medicinal Chemistry Letters (2020)
a=10.7972(5)Å b=4.73210(10)Å c=13.9575(6)Å
α=90° β=111.019(5)° γ=90°
Ent-21
C20H18N2O
ACS Medicinal Chemistry Letters (2020)
a=9.8446(8)Å b=5.8701(5)Å c=13.6268(11)Å
α=90° β=101.772(6)° γ=90°
Ent-13
C15H16N2O2
ACS Medicinal Chemistry Letters (2020)
a=5.7224(3)Å b=9.4414(5)Å c=23.8273(12)Å
α=90° β=90° γ=90°
7
C18H22N2O
ACS Medicinal Chemistry Letters (2020)
a=16.3071(3)Å b=4.73520(10)Å c=19.7305(4)Å
α=90° β=97.8660(10)° γ=90°
20
C27H25N3O4
ACS Medicinal Chemistry Letters (2020)
a=13.777(6)Å b=5.073(2)Å c=15.860(6)Å
α=90° β=103.272(7)° γ=90°
Ent-14
C15H16N2O2
ACS Medicinal Chemistry Letters (2020)
a=9.9840(9)Å b=5.4028(3)Å c=12.6101(10)Å
α=90° β=111.475(6)° γ=90°
Ent-22
C19H17N3O
ACS Medicinal Chemistry Letters (2020)
a=5.3519(2)Å b=10.5670(4)Å c=26.7767(11)Å
α=90° β=90° γ=90°
8
C38H55ClN4O5
ACS Medicinal Chemistry Letters (2020)
a=6.81630(10)Å b=9.5313(2)Å c=15.3468(2)Å
α=73.148(2)° β=77.8340(10)° γ=89.575(2)°
Ent-30
C17H16N4O
ACS Medicinal Chemistry Letters (2020)
a=9.6081(4)Å b=5.9379(2)Å c=13.0825(5)Å
α=90° β=102.380(2)° γ=90°
C13H19BrN2O3
C13H19BrN2O3
Journal of Organic Chemistry (2011) 76, 2694-2700
a=6.0781(19)Å b=12.324(4)Å c=19.719(6)Å
α=90.00° β=90.00° γ=90.00°
Dichloride[Bis(1-(2-(5-Methylfuryl)methylene)-2-(2-(5-methylfuryl))benzimidazo le)]copper(II)
C36H32Cl2CuN4O4
Organometallics (2002) 21, 21 4350
a=22.150(6)Å b=9.363(3)Å c=17.882(5)Å
α=90.00° β=115.561(5)° γ=90.00°
Dichloro[bis((1-(2-furyl)methylene)-2-(2-furyl)benzimidazole)]cobalt(II)
C32H24Cl2CoN4O4
Organometallics (2002) 21, 21 4350
a=15.592(3)Å b=11.115(2)Å c=18.439(4)Å
α=90.00° β=111.89(3)° γ=90.00°
C9H11NO4
C9H11NO4
Zeitschrift für Kristallographie - New Crystal Structures (2009) 224, 2 183
a=7.8446(14)Å b=8.5168(15)Å c=14.468(3)Å
α=88.441(3)° β=83.235(3)° γ=70.919(3)°